J 2018

Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia

PLEŠINGEROVÁ, Hana, Pavlína JANOVSKÁ, Ashish Kumar MISHRA, Lucie SMYČKOVÁ, Lucie POPPOVÁ et. al.

Basic information

Original name

Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia

Authors

PLEŠINGEROVÁ, Hana (203 Czech Republic, belonging to the institution), Pavlína JANOVSKÁ (203 Czech Republic, belonging to the institution), Ashish Kumar MISHRA (356 India, belonging to the institution), Lucie SMYČKOVÁ (203 Czech Republic, belonging to the institution), Lucie POPPOVÁ (203 Czech Republic, belonging to the institution), A. LIBRA (203 Czech Republic), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Lenka RADOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Šárka PAVLOVÁ (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution) and Vítězslav BRYJA (203 Czech Republic, guarantor, belonging to the institution)

Edition

Haematologica/the hematology journal, Fondazione Ferrata Storti, 2018, 0390-6078

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 7.570

RIV identification code

RIV/00216224:14310/18:00100795

Organization unit

Faculty of Science

UT WoS

000423853800028

Keywords in English

CHIMERIC ANTIGEN RECEPTOR; B-CELLS; MUTATIONAL STATUS; T-CELLS; GENE; CLL; PATHWAY; DIFFERENTIATION; PATHOGENESIS; CHEMOTAXIS

Tags

International impact, Reviewed
Změněno: 23/4/2024 10:58, Mgr. Michal Petr

Abstract

V originále

Chronic lymphocytic leukemia is a disease with up-regulated expression of the transmembrane tyrosine-protein kinase ROR1, a member of the Wnt/planar cell polarity pathway. In this study, we identified COBLL1 as a novel interaction partner of ROR1. COBLL1 shows clear bimodal expression with high levels in chronic lymphocytic leukemia patients with mutated IGHV and approximately 30% of chronic lymphocytic leukemia patients with unmutated IGHV. In the remaining 70% of chronic lymphocytic leukemia patients with unmutated IGHV, COBLL1 expression is low. Importantly, chronic lymphocytic leukemia patients with unmutated IGHV and high COBLL1 have an unfavorable disease course with short overall survival and time to second treatment. COBLL1 serves as an independent molecular marker for overall survival in chronic lymphocytic leukemia patients with unmutated IGHV. In addition, chronic lymphocytic leukemia patients with unmutated IGHV and high COBLL1 show impaired motility and chemotaxis towards CCL19 and CXCL12 as well as enhanced B-cell receptor signaling pathway activation demonstrated by increased PLC gamma 2 and SYK phosphorylation after IgM stimulation. COBLL1 expression also changes during B-cell maturation in non-malignant secondary lymphoid tissue with a higher expression in germinal center B cells than naive and memory B cells. Our data thus suggest COBLL1 involvement not only in chronic lymphocytic leukemia but also in B-cell development. In summary, we show that expression of COBLL1, encoding novel ROR1-binding partner, defines chronic lymphocytic leukemia sub-groups with a distinct response to microenvironmental stimuli, and independently predicts survival of chronic lymphocytic leukemia with unmutated IGHV.

Links

GA17-09525S, research and development project
Name: Neobvyklé signální dráhy lidských receptorových tyrozinových kináz
Investor: Czech Science Foundation
GA17-16680S, research and development project
Name: Nové postupy pro určení aktivity dráhy planární buněčné polarity (PCP)
Investor: Czech Science Foundation
LQ1601, research and development project
Name: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/0988/2016, interní kód MU
Name: Podpora výzkumné činnosti studentů v oblasti fyziologie a imunologie živočichů v roce 2017
Investor: Masaryk University, Category A
MUNI/A/1106/2016, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Acronym: VýDiTeHeMA IV)
Investor: Masaryk University, Category A
NV15-29793A, research and development project
Name: Analýza Wnt/PCP jako nástroj pro lepší management chronické lymfocytární leukémie